Status | Study |
Active, not recruiting |
Study Name: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2013-01-24 Interventions: Drug: Bendamustine 90 mg/m2 ad |
Completed |
Study Name: Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Condition: Mantle Cell Lymphoma Date: 2012-07-18 Interventions: Drug: Ibrutinib 560 mg once da |
Active, not recruiting |
Study Name: Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2012-06-26 Interventions: Drug: Rituximab, Bendamustine, Cytarabine. 6 cycles of 28 days with Rituximab, Bendamustine and Cytarabi |
Completed |
Study Name: A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy Condition: Mantle Cell Lymphoma Date: 2012-05-14 Interventions: Drug: Ibrutinib Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibruti |
Completed |
Study Name: Study of Mantle Cell Lymphoma Treatment by RiBVD Condition: Mantle Cell Lymphoma Date: 2011-10-20 Interventions: Drug: RiBVD Every cycle: |
Active, not recruiting |
Study Name: Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) Condition: Mantle Cell Lymphoma Date: 2011-08-16 Interventions: Drug: Rituximab 375 mg/m2 on d |
Active, not recruiting |
Study Name: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2011-03-24 Interventions: Drug: lenalidomide |
Completed |
Study Name: Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Recurrent Date: 2011-03-24 Interventions: Drug: Combination of Bortezomib, Fludarabine and Cyclophosphamide bortezomib 1.3mg/m^2 i.v. on days 1, 4 |
Active, not recruiting |
Study Name: Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Condition: Mantle Cell Lymphoma Date: 2009-08-20 Interventions: Drug: lenalidomide, bendamustine, rituximab |
Recruiting |
Study Name: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma Condition: Mantle-Cell Lymphoma Date: 2009-04-07 Interventions: Biological: G-CSF Granulocyte- |